S1200 Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study
American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S853-S854
10.14309/01.ajg.0001034168.98973.2c